Labiotech.eu

Interview 26 Apr 2017

Infographic: Who’s who in the mRNA Therapeutics Field in Europe?

The young field of mRNA therapeutics is booming and generating huge expectations. Which are the main players in Europe turning them into a reality? Therapies based on mRNA promise better vaccines and therapeutics by instructing the body to produce its own just by reading the instructions written in the RNA sequence. Thought for a long time to […]

April 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 25 Apr 2017

Novartis Negotiates its Way into the US Migraine Market

Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […]

April 25, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 25 Apr 2017

EMA designates uniQure’s gene therapy for hemophilia a priority

Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial failure, uniQure has been on the rebound. The company recently has undergone several management shakeups and a strategy review, and it just made the decision to withdraw […]

April 25, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 25 Apr 2017

New Research could Save Patients from Graft-Versus-Host Disease

A new study published in the journal Science Translational Medicine identifies a new treatment strategy to prevent GVHD after stem cell transplantation. Allogeneic stem cell transplantation remains one of the top treatments for blood cancers and inherited blood disorders, but the treatment is associated with a major risk of so-called graft-versus-host disease (GVHD). A new paper […]

April 25, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 24 Apr 2017

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […]

April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview Mark Post cultured meat Mosa Meat

Interview 24 Apr 2017

‘Meat’ the Founder behind the Lab-Grown Burger Investors are Queuing for

Mark Post is a researcher at the University of Maastricht and co-founder and CSO of Mosa Meat, the Dutch company that will bring the first lab-grown beef burger to the market. I asked him about his motivations and plans to make cultured meat a reality in the coming decade. Cultured meat is an animal-free, lab-grown […]

April 24, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Apr 2017

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […]

April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Apr 2017

The World’s Most Expensive Drugs have European Owners

A new report has listed the world’s most expensive drugs. Not surprisingly, those targeting rare diseases bear the heaviest price tags – let’s have a look. While biotechs like Généthon and EspeRare are rethinking the high-risk high-profit model and looking to provide treatments at an affordable price, most rare disease meds on the market are among the most […]

April 21, 2017 - 4 minutesmins - By Melanie De Almeida

fungi secondary metabolites genome sequencing

News and Trends 21 Apr 2017

Fungi Genomes could be a Gold Mine of New Antibiotics

Good old Penicillium still has a lot more tricks upon its sleeve: Swedish researchers see its potential as a gold mine for new antibiotics. The genomic analysis of Penicillium species represents a potential gold mine for new bioactive compounds, or improved versions of those we already use. Published recently in Nature Microbiology, the work was carried at Chalmers University […]

April 21, 2017 - 3 minutesmins - By Denise Neves Gameiro

Startup Scout 21 Apr 2017

No more Needles – This UK Biotech is Developing Innovative Oral Vaccines

The small village of Keele is probably best known for its university, but it also hosts the Keele Science Park, where the biotech company Prokarium is developing new oral vaccine solutions based on synthetic biology. Mission: Prokarium has the vision that all protein vaccines can be delivered orally. Founded in 2012, the company has developed an oral […]

April 21, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 20 Apr 2017

Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn

The excitement about the therapy was undercut when it became clear Glybera would be a commercial failure. In October, it will officially be dead. uniQure has announced that it will not go for the renewal of its marketing authorization for Glybera in Europe, which is set to expire in October this year. Since Glybera missed approval in the […]

April 20, 2017 - 3 minutesmins - By Evelyn Warner

Stefan Weber CEO Newron Pharmaceuticals Labiotech Meetup Munich

Interview 20 Apr 2017

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

Philip talked to Stefan Weber, CEO of Newron Pharmaceuticals, in our first meetup in Munich last week. His company has launched a new drug that could offer many more benefits than current medications to patients with Parkinson’s. Stefan discussed how failure can be an important part of success and what being European means in biotech. […]

April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Infographic: Who’s who in the mRNA Therapeutics Field in Europe?

Novartis Negotiates its Way into the US Migraine Market

EMA designates uniQure’s gene therapy for hemophilia a priority

New Research could Save Patients from Graft-Versus-Host Disease

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

‘Meat’ the Founder behind the Lab-Grown Burger Investors are Queuing for

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

The World’s Most Expensive Drugs have European Owners

Fungi Genomes could be a Gold Mine of New Antibiotics

No more Needles – This UK Biotech is Developing Innovative Oral Vaccines

Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!